Alzheimercentrum Amsterdam

Publicaties 2010

Internationale wetenschappelijk publicaties (peer reviewed):

  • Archer HA, Kennedy J, Barnes J, Pepple T, Boyes R, Randlesome K, Clegg S, Leung KK, Ourselin S, Frost C, Rossor MN, Fox NC. Memory complaints and increased rates of brain atrophy: risk factors for mild cognitive impairment and Alzheimer’s disease. Int J Geriatr Psychiatry 2010;25:1119-1126.
  • Babiloni C, Visser PJ, Frisoni G, De Deyn PP, Bresciani L, Jelic V, Nagels G, Rodriguez G, Rossini PM, Vecchio F, Colombo D, Verhey F, Wahlund L-O, Nobili F. Cortical sources of resting EEG rhythms in mild cognitive impairment and subjective memory complaint. Neurobiol Aging 2010;31:1787-1798.
  • Barnes J, Mitchell LA, Kennedy J, Bastos-Leite AJ, Barker S, Lehmann M, Nordstrom RC, Frost C, Smith JR, Garde E, Rossor MN, Fox NC. Does registration of serial MRI improve diagnosis of dementia? Neuroradiology 2010;52:987-995.
  • Barnes J, Ridgway GR, Bartlett J, Henley SMD, Lehmann M, Hobbs N, Clarkson MJ, Macmanus DG, Ourselin S, Fox NC.  Head size, age and gender adjustment in MRI studies: A necessary nuisance?  Neuroimage 2010;53:1244-1255.
  • Bird CM, Chan D, Hartley T, Pijnenburg YA, Rossor MN, Burgess N. Topographical short-term memory differentiates Alzheimer’s disease from frontotemporal lobar degeneration. Hippocampus 2010;20:1154-1169.
  • Bour AMJJ, Rasquin SMC, Baars L, van Boxtel MPJ, Visser PJ, Limburg M, Verhey FRJ. The effect of the APOE-ε4 allele and ACE-I/D polymorphism on cognition during a two-year follow-up in first-ever stroke patients. Dement Geriatr Cogn Disord 2010;29:534-542.
  • Bouwman FH, Verwey NA, Klein M, Kok A, Blankenstein MA, Sluimer JD, Barkhof F,van der Flier WM, Scheltens P. New research criteria for the diagnosis of Alzheimer’s disease applied in a memory clinic population.  Dement Geriatr Cogn Disord 2010;30:1-7.
  • Carmichael O, Schwarz C, Drucker D, Fletcher E, Harvey D, Beckett L, Jack CR Jr, Weiner M, DeCarli C, for the Alzheimer’s Disease Neuroimaging Initiative.(waaronder Visser PJ)Longitudinal changes in white matter disease and cognition in the first year of the Alzheimer disease neuroimaging initiative. Arch Neurol 2010;67:1370-1378.
  • Chouliaras L, Rutten BPF, Kenis G, Peerbooms O, Visser PJ, Verhey F, van Os J, Steinbusch HWM, van den Hove DLA. Epigenetic regulation in the pathophysiology of Alzheimer’s disease. Prog Neurobiol 2010;90:498-510.
  • Clarkson MJ, Malone IB, Modat M, Leung KK, Ryan N, Alexander DC, Fox NC, Ourselin S. A framework for using diffusion weighted imaging to improve cortical parcellation. Med Image Comput Comput Assist Interv. 2010;13:534-541.
  • Delaloye C, Moy G, de Bilbao F, Baudois S, Weber K, Hofer F, Paquier CR, Donati A, Canuto A, Giardini U, von Gunten A, Stancu RI, Lazeyras F, Millet P, Scheltens P, Giannakopoulos P, Gold G. Neuroanatomical and neuropsychological features of elderly euthymic depressed patients with early- and late-onset. J Neurol Sci 2010;299:19-23.
  • Dubois B, Feldman HH, Jacova C, Cummings JL, Dekosky ST, Barberger-Gateau P, Delacourte A, Frisoni G, Fox NC, Galasko D, Gauthier S, Hampel H, Jicha GA, Meguro K, O’Brien J, Pasquier F, Robert P, Rossor M, Salloway S, Sarazin M, de Souza LC, Stern Y, Visser PJ, Scheltens P. Revising the definition of Alzheimer’s disease: a new lexicon. Lancet Neurol 2010;9:1118-1127.
  • Evans MC, Barnes J, Nielsen C, Kim LG, Clegg SL, Blair M, Leung KK, Douiri A, Boyes RG, Ourselin S, Fox NC, and the Alzheimer’s Disease Neuroimaging Initiative.  Volume changes in Alzheimer’s disease and mild cognitive impairment: cognitive associations. Eur Radiol 2010;20:674-682.
  • Exalto LG, van der Flier WM, Scheltens P, Biessels GJ. Glycemia and levels of cerebrospinal fluid amyloid and tau in patients attending a memory clinic.  J Am Geriatr Soc 2010;58:1318-1321.
  • Fox N. Clinical advances in our understanding and classification of the dementias. J Neurol Neurosurg Psychiatry 2010;81(10):e3,006.
  • Frisoni GB, Fox NC, Jack CR Jr, Scheltens P, Thompson PM. The clinical use of structural MRI in Alzheimer disease.  Nat Rev Neurol 2010;6:67-77.
  • Goos JDC, Henneman WJP, Sluimer JD, Vrenken H, Sluimer IC, Barkhof F, Blankenstein MA, Scheltens PH, van der Flier WM. Incidence of cerebral microbleeds: A longitudinal study in a memory clinic population. Neurology 2010;74:1954-1960.
  • Gordon E, Rohrer JD, Kim LG, Omar R, Rossor MN, Fox NC, Warren JD. Measuring disease progression in frontotemporal lobar degeneration: a clinical and MRI study. Neurology 2010:74: 666-673.
  • Guerreiro RJ, Beck J, Gibbs JR, Santana I, Rossor MN, Schott JM, Nalls MA, Ribeiro H, Santiago B, Fox NC, Oliveira C, Collinge J, Mead S, Singleton A, Hardy J.  Genetic variability inCLU and its association with Alzheimer’s disease.  PLoS One 2010;5(3):e9510.
  • Henley SMD, Ridgway GR, Scahill RI, Klöppel S, Tabrizi SJ, Fox NC, Kassubek J, for the EHDN Imaging Working Group. Pitfalls in the Use of Voxel-Based Morphometry as a Biomarker: Examples from Huntington Disease. AJNR Am J Neuroradiol 2010;31:711-719.
  • Hobbs NZ, Barnes J, Frost C, Henley SMD, Wild EJ, Macdonald K, Barker RA, Scahill RI, Fox NC, Tabrizi SJ. Onset and progression of pathologic atrophy in Huntington disease: a longitudinal MR imaging study. AJNR Am J Neuroradiol 2010;31:1036-1041.
  • Hobbs NZ, Henley SMD, Ridgway G, Wild EJ, Barker R, Scahill RI, Barnes J, Fox NC, Tabrizi SJ. The progression of regional atrophy in premanifest and early Huntington’s disease: a longitudinal voxel-based morphometry study. J Neurol Neurosurg Psychiatry 2010;81:756-763.
  • Hort J, O’Brien JT, Gainotti G, Pirttila T, Popescu BO, Rektorova I, Sorbi S, Scheltens P, on Behalf of the EFNS Scientist Panel on Dementia. EFNS guidelines for the diagnosis and management of Alzheimer’s disease. Eur J Neurol 2010;17:1236-1248.
  • Hort J, Bartos A, Pirttilä T, Scheltens P. Use of cerebrospinal fluid biomarkers in diagnosis of dementia across Europe.  Eur J Neurol 2010;17:90-96.
  • Hyare H, Wroe S, Siddique D, Webb T, Fox NC, Stevens J, Collinge J, Yousry T, Thornton JS. Brain-water diffusion coefficients reflect the severity of inherited prion disease. Neurology 2010;74:658-665.
  • Jack CR Jr, Bernstein MA, Borowski BJ, Gunter JL, Fox NC, Thompson PM, Schuff N, Krueger G, Killiany RJ, DeCarli CS, Dale AM, Carmichael OW, Tosun D, Weiner MW and the Alzheimer’s Disease Neuroimaging Initiative.  Update on the magnetic resonance imaging core of the Alzheimer’s disease neuroimaging initiative.  Alzheimers Dement 2010;6:212-220.
  • Joling KJ, van Hout HPJ, Schellevis FG, van der Horst HE, Scheltens P, Knol DL, van Marwijk HWJ. Incidence of depression and anxiety in the spouses of patients with dementia: a naturalistic cohort study of recorded morbidity with a 6-year follow-up. Am J Geriatr Psychiatry 2010;18:146-153.
  • Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A, Pahwa JS, Jones N, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Mead S, Fox N, et al. Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer’s disease. PLoS One 2010;5(11):e13950.
  • Jonsson M, Zetterberg H, van Straaten E, Lind K, Syversen S, Edman A, Blennow K, Rosengren L, Pantoni L, Inzitari D, Wallin A. Cerebrospinal fluid biomarkers of white matter lesions – cross-sectional results from the LADIS study. Eur J Neurol 2010;17:377-382.
  • Kamphuis PJGH, Scheltens P. Can nutrients prevent or delay onset of Alzheimer’s disease? J Alzheimers Dis 2010;20:765-775.
  • Keihaninejad S, Heckemann RA, Fagiolo G, Symms MR, Hajnal JV, Hammers A, Alzheimer’s Disease Neuroimaging Initiative.(waaronder Fox NC) A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T). Neuroimage 2010;50:1427-1437.
  • Kester MI, Boelaarts L, Bouwman FH, Vogels RL, Groot ER, van Elk EJ, Blankenstein MA, van der Flier WM, Scheltens P. Diagnostic impact of CSF biomarkers in a local hospital memory clinic. Dement Geriatr Cogn Disord 2010;29:491-497.
  • Kester MI, Verwey NA, van Elk EJ, Scheltens P, Blankenstein MA. Evaluation of plasma Aβ40 and Aβ42 as predictors of conversion to Alzheimer’s disease in patients with mild cognitive impairment. Neurobiol Aging 2010;31:539-540.
  • Kester MI, van der Flier WM, Mandic G, Blankenstein MA, Scheltens P, Muller M. Joint effect of hypertension and APOE genotype on CSF biomarkers for Alzheimer’s disease.
  • J Alzheimers Dis 2010;20:1083-1090.
  • Keihaninejad S, Heckemann RA, Fagiolo G, Symms MR, Hajnal JV, Hammers A, Alzheimer’s Disease Neuroimaging Initiative (waaronder Fox N). A robust method to estimate the intracranial volume across MRI field strengths (1.5T and 3T). Neuroimage 2010;50:1427-1437.
  • Koedam ELGE, Van der Flier WM, Barkhof F, Koene T, Scheltens P, Pijnenburg YAL. Clinical characteristics of patients with frontotemporal dementia with and without lobar atrophy on MRI. Alzheimer Dis Assoc Disord 2010;24:242-247.
  • Koedam ELGE, Lauffer V, van der Vlies AE, van der Flier WM, Scheltens P, Pijnenburg YAL. Early- versus late-onset Alzheimer’s disease: more than age alone. J Alzheimers Dis 2010;19:1401-1408.
  • Lehmann M, Douiri A, Kim LG, Modat M, Chan D, Ourselin S, Barnes J, Fox NC. Atrophy patterns in Alzheimer’s disease and semantic dementia: A comparison of FreeSurfer and manual volumetric measurements. Neuroimage 2010;49:2264-2274.
  • Lehmann M, Rohrer JD, Clarkson MJ, Ridgway GR, Scahill RI, Modat M, Warren JD, Ourselin S, Barnes J, Rossor MN, Fox NC. Reduced cortical thickness in the posterior cingulate gyrus is characteristic of both typical and atypical Alzheimer’s disease. J Alzheimers Dis 2010;20:587-598.
  • Leung KK, Barnes J, Ridgway GR, Bartlett JW, Clarkson MJ, Macdonald K, Schuff N, Fox NC, Ourselin S, and  the Alzheimer’s Disease Neuroimaging Initiative. Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer’s disease.  Neuroimage 2010;51:1345-1359.
  • Leung KK, Shen KK, Barnes J, Ridgway GR, Clarkson MJ, Fripp J, Salvado O, Meriaudeau F, Fox NC, Bourgeat P, Ourselin S, Increasing power to predict mild cognitive impairment conversion to Alzheimer’s disease using hippocampal atrophy rate and statistical shape models. Med Image Comput Comput Assist Interv. 2010;13:125-132.
  • Leung KK, Clarkson MJ, Bartlett JW, Clegg S, Jack CR Jr, Weiner MW, Fox NC, Ourselin S, and the Alzheimer’s Disease Neuroimaging Initiative. Robust atrophy rate measurement in Alzheimer’s disease using multi-site serial MRI: tissue-specifi c intensity normalisation and parameter selection.  Neuroimage 2010;50:516-523.
  • Liedorp M, Stam CJ, van der Flier WM, Pijnenburg YAL, Scheltens Ph. Prevalence and clinical significance of epileptiform EEG discharges in a large memory clinic cohort. Dement Geriatr Cogn Disord 2010;29:432-437.
  • Madureira S, Verdelho A, Moleiro C, Ferro JM, Erkinjuntti T, Jokinen H, Pantoni L, Fazekas F, van der Flier W, Visser M, Waldemar G, Wallin A, Hennerici M, Inzitari D. Neuropsychological predictors of dementia in a three-year follow-up period: data from the LADIS study. Dement Geriatr Cogn Disord 2010;29:325-334.
  • Mihaescu R, Detmar SB, Cornel MC, van der Flier WM, Heutink P, Hol EM, Olde Rikkert MGM, van Duijn CM, Janssens ACJW. Translational research in genomics of Alzheimer’s disease: a review of current practice and future perspectives. J Alzheimers Dis 2010;20:967-980.
  • Modat M, Ridgway GR, Taylor ZA, Lehmann M, Barnes J, Hawkes DJ, Fox NC, Ourselin S. Fast free-form deformation using graphics processing units.
  • Comput Methods Programs Biomed 2010;98:278-184.
  • Mulder C, Verwey NA, van der Flier WM, Bouwman FH, Kok A, van Elk EJ, Scheltens P, Blankenstein MA. Amyloid-β(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin Chem 2010;56:248-253.
  • Mulder SD, van der Flier WM, Verheijen JH, Mulder C, Scheltens P, Blankenstein MA, Hack CE, Veerhuis R. BACE1 activity in cerebrospinal fluid and its relation to markers of AD pathology. J Alzheimers Dis 2010;20:253-260.
  • Mulder SD, Hack CE, van der Flier WM, Scheltens P, Blankenstein MA, Veerhuis R. Evaluation of intrathecal serum amyloid P (SAP) and C-reactive protein (CRP) synthesis in Alzheimer’s disease with the use of index values. J Alzheimers Dis 2010;22:1073-1079.
  • Oosterman JM, Vogels RLC, van Harten B, Gouw AA, Poggesi A, Scheltens P, Kessels RPC, Scherder EJA. Assessing mental flexibility: neuroanatomical and neuropsychological correlates of the trail making test in elderly people. Clin Neuropsychol 2010;24:203-219.
  • Petzold A, Verwey NA, van Uffelen K, Blankenstein MA, Teunissen C. Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration. J Neurosci Methods 2010;193:296-299.
  • Petzold A, Chapman MD, Schraen S, Verwey NA, Pasquier F, Bombois S, Brettschneider J, Fox NC, von Arnim CAF, Teunissen C, Pijnenburg Y, Riepe MW, Otto M, Tumani H, Scheltens P, Buee L, Rosso MN. An unbiased, staged, multi-center, validation strategy for Alzheimer’s disease CSF tau levels. Exp Neurol 2010;223:432-438.
  • Polvikoski TM, van Straaten ECW, Barkhof F, Sulkava R, Aronen HJ, Niinistö L, Oinas M, Scheltens P, Erkinjuntti T, Kalaria RN. Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. Neurology 2010;75:2071-2078.
  • Prins ND, van Swieten JC. Alzheimer disease: MRI and CSF biomarkers in AD-accuracy and temporal change. Nat Rev Neurol 2010:6:650-651.
  • Prins ND, Visser PJ, Scheltens P. Can novel therapeutics halt the amyloid cascade? Alzheimers Res Ther 2010;2(2):5.
  • Ramakers IHGB, Visser PJ, Aalten P, Kester A, Jolles J, Verhey FRJ. Affective symptoms as predictors of Alzheimer’s disease in subjects with mild cognitive impairment: a 10-year follow-up study.  Psychol Med 2010;40:1193-1201.
  • Ramakers IHGB, Visser PJ, Aalten P, Maes HL, Lansdaal HGM, Meijs CJC, Jolles J, Verhey FR. The predictive value of memory strategies for Alzheimer’s disease in subjects with mild cognitive impairment. Arch Clin Neuropsychol 2010;25:71-77.
  • Reesink FE, Lemstra AW, van Dijk KD, Berendse HW, van de Berg WDJ, Klein M, Blankenstein MA, Scheltens P, Verbeek MM, van der Flier WM. CSF α-synuclein does not discriminate dementia with lewy bodies from Alzheimer’s disease. J Alzheimers Dis 2010;22:87-95.
  • Richard E, Gouw AA, Scheltens P, van Gool WA. Vascular care in patients with Alzheimer disease with cerebrovascular lesions slows progression of white matter lesions on MRI. The evaluation of vascular care in Alzheimer’s disease (EVA) study. Stroke 2010;41:554-556.
  • Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, Mathis CA, Blennow K, Barakos J, Okello AA, de Liano SR, Liu E, Koller M, Gregg KM, Schenk D, Black R, Grundman M. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-372.
  • Rohrer JD, Ridgway GR, Modat M, Ourselin S, Mead S, Fox NC, Rossor MN, Warren JD. Distinct profiles of brain atrophy in frontotemporal lobar degeneration caused by progranulin and tau mutations. Neuroimage 2010;53:1070-1076.
  • Rossor MN, Fox NC, Mummery CJ, Schott JM, Warren JD. The diagnosis of young-onset dementia. Lancet Neurol 2010;9:793-806.
  • van Rossum IA, ten Houten R. Alledaagse symptomen als uiting van MELAS. Ned Tijdschr Geneeskd 2010;154:A2168.
  • van Rossum IA, Vos S, Handels R, Visser PJ. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J Alzheimers Dis 2010;20:881-891.
  • Salloway SP, Black R, Sperling R, Fox N, Gilman S, Schenk D, Griundman Ml.  Reply from the authors: A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2010;74(24):2026-2027.
  • Sanz-Arigita EJ, Schoonheim MM, Damoiseaux JS, Rombouts SARB, Maris E, Barkhof F, Scheltens P, Stam CJ. Loss of ‘small-world’ networks in Alzheimer’s disease: graph analysis of FMRI resting-state functional connectivity. PLoS One 2010;5(11):e13788.
  • Scheltens P, Kamphuis PJGH, Verhey FRJ, Olde Rikkert MGM,  Wurtman RJ,  Wilkinson D, Twisk JWR, Kurz A. Efficacy of a medical food in mild Alzheimer’s disease: a randomized, controlled trial. Alzheimers Dement  2010;6:1-10
  • Schmidt R, Ropele S, Ferro J, Madureira S, Verdelho A, Petrovic K, Gouw A, van der Flier WM, Enzinger C, Pantoni L, Inzitari D, Erkinjuntti T, Scheltens P, Wahlund LO, Waldemar G, Rostrup E, Wallin A, Barkhof F, Fazekas F, on behalf of the LADIS study group. Diffusion-weighted imaging and cognition in the leukoariosis and disability in the elderly study.  Stroke 2010;41:e402-e408.
  • Schneider LS, Kennedy RE, Cutter GR, and the Alzheimer’s Disease Neuroimaging Initiative. (waaronder Fox N.)Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer’s disease or mild cognitive impairment does not lead to more efficient clinical trials. Alzheimers Dement 2010;6:367-377.
  • Schott JM, Bartlett JW, Fox NC, Barnes J, for the Alzheimer’s Disease Neuroimaging Initiative Investigators. Increased brain atrophy rates in cognitively normal older adults with low cerebrospinal fluid Aβ1-42. Ann Neurol 2010;68:825-834.
  • Schott JM, Bartlett JW, Barnes J, Leung KK, Ourselin S, Fox NC, for the Alzheimer’s Disease Neuroimaging Initiative Investigators. Reduced sample sizes for atrophy outcomes in Alzheimer’s disease trials: baseline adjustment. Neurobiol Aging 2010;31:1452-1462.
  • Schott JM, Frost C, Macmanus DG, Ibrahim F, Waldman AD, Fox NC. Short echo time proton magnetic resonance spectroscopy in Alzheimer’s disease: a longitudinal multiple time point study. Brain 2010;133:3315-3322.
  • Schuitemaker A, Dik MG, Veerhuis R, Scheltens P, Schoonenboom NSM, Hack CE, Blankenstein MA, Jonker C. Inflammatory markers in AD and MCI patients with different biomarker profiles-interpretation of serum and CSF levels. Neurobiol Aging 2010;31:1655.
  • Shen L, Kim S, Risacher SL, Nho K, Swaminathan S, West JD, Foroud T, Pankratz N, Moore JH, Sloan CD, Huentelman MJ, Craig DW, Dechairo BM, Potkin SG, Jack CR Jr, Weiner MW, Saykin AJ and the Alzheimer’s Disease Neuroimaging Initiative.( waaronder Fox N ). Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage 2010;53:1051-1063.
  • Sikkes SAM, van den Berg MT, Knol DL, de Lange-de Klerk ESM, Scheltens P, Uitdehaag BMJ, Klein M, Pijnenburg YAL. How useful Is the IQCODE for discriminating between Alzheimer’s disease, mild cognitive impairment and subjective memory complaints? Dement Geriatr Cogn Disord 2010;30:411-416.
  • Slats D, Spies PE, Sjögren MJC, Visser PJ, Verbeek MM, Rikkert MGM, Kehoe PG. CSF biomarker utilisation and ethical considerations of biomarker assisted diagnosis and research in dementia: perspectives from within the European Alzheimer’s Disease Consortium (EADC). J Neurol Neurosurg Psychiatry 2010;81:124-125.
  • Sluimer JD, Bouwman FH, Vrenken H, Blankenstein MA, Barkhof F, van der Flier WM, Scheltens P. Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging 2010;31:758-764.
  • Smits LL, Liedorp M, Koene T, Roos-Reuling IEW, Lemstra AW, Scheltens P, Stam CJ, van der Flier WM. EEG abnormalities are associated with different cognitive profiles in Alzheimer’s disease. Dement Geriatr Cogn Disord 2010;31:1-6.
  • Staekenborg SS, Su T, van Straaten ECW, Lane R, Scheltens P, Barkhof F, van der Flier WM. Behavioural and psychological symptoms in vascular dementia; differences between small and large vessel disease. J Neurol Neurosurg Psychiatry 2010;81:547-551.
  • Staekenborg SS, de Waal H, Admiraal-Behloul F, Barkhof F, Reiber JHC, Scheltens P, Pijnenburg YAL, Vrenken H, van der Flier WM. Neurological signs in relation to white matter hyperintensity volumes in memory clinic patients.  Dement Geriatr Cogn Disord 2010;29:301-308.
  • Teodorczuk A, Firbank MJ, Pantoni L, Poggesi A, Erkinjuntti T, Wallin A, Wahlund L-O, Scheltens P, Waldemar G, Schrotter G, Ferro JM, Chabriat H, Bazner H, Visser M, Inzitari D, O’Brien JT, on behalf of the LADIS Group. Relationship between baseline white-matter changes and development of late-life depressive symptoms: 3-year results from the LADIS study. Psychol Med 2010;40:603-610.
  • Teunissen CE, Verwey NA, Kester MI, van Uffelen K, Blankenstein MA. Standardization of assay procedures for analysis of the CSF biomarkers amyloid β(1-42)), tau, and phosphorylated tau in Alzheimer’s disease: report of an International workshop.
  • Int J Alzheimers Dis 2010; Article ID 635053:1-6.
  • Tolboom N, Koedam ELGE, Schott JM, Yaqub M, Blankenstein MA, Barkhof F, Pijnenburg YAL, Lammertsma AA, Scheltens P, van Berckel BNM. Dementia mimicking Alzheimer’s disease owing to a tau mutation: CSF and PET findings.  Alzheimer Dis Assoc Disord 2010;24:303-307.
  • Tolboom N, van der Flier WM, Boverhoff J, Yaqub M, Wattjes MP, Raijmakers PG, Barkhof F, Scheltens P, Herholz K, Lammertsma AA, van Berckel BNM. Molecular imaging in the diagnosis of Alzheimer’s disease: visual assessment of [11C]PIB and [18F]FDDNP PET images. J Neurol Neurosurg Psychiatry 2010;81:882-884.
  • Tsolaki M, Papaliagkas V, Anogianakis G, Bernabei R, Emre M, Frolich L, Visser PJ, Michel J-P, Pirttila T, Olde Rikkert M, Soininen H, Sobow T, Vellas B, Verhey F, Winblad B and the European Alzheimer’s Disease Consortium. Consensus statement on dementia education and training in Europe. J Nutr Health Aging 2010;14:131-135.
  • Verdelho A, Madureira S, Moleiro C, Ferro JM, Santos CO, Erkinjuntti T, Pantoni L, Fazekas F, Visser M, Waldemar G, Wallin A, Hennerici M, Inzitari D, on behalf of the LADIS Study. White matter changes and diabetes predict cognitive decline in the elderly: The LADIS Study. Neurology 2010;75:160-167.
  • Verwey NA, Kester MI, van der Flier WM, Veerhuis R, Berkhof H, Twaalfhoven H, Blankenstein MA, Scheltens P, Pijnenburg YAL. Additional value of CSF amyloid-β40 levels in the differentiation between FTLD and control subjects. J Alzheimers Dis 2010;20:445-452.
  • VITATOPS Trial Study Group (waaronder Eikelenboom JW, Koedam E). B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial.  Lancet Neurol 2010;9:855-865.
  • Vounou M, Nichols TE, Montana G and the  Alzheimer’s Disease Neuroimaging Initiative (waaronder Fox N). Discovering genetic associations with high-dimensional neuroimaging phenotypes: A sparse reduced-rank regression approach. Neuroimage 2010;53:1147-1159.
  • Wild EJ, Henley SMD, Hobbs NZ, Frost C, MacManus DG, Barker RA, Fox NC, Tabrizi SJ. Rate and acceleration of whole-brain atrophy in premanifest and early Huntington’s disease. Mov Disord 2010;25:888-895.
  • Wolk DA, Dickerson BC and the Alzheimer’s Disease Neuroimaging Initiative, (waaronder Fox NC) Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer’s disease. Proc Natl Acad Sci U S A 2010;107:10256-10261.
  • Yaqub M, Tolboom N, van Berckel BNM, Scheltens P, Lammertsma AA, Boellaard R. Simplified parametric methods for [18F]FDDNP studies. Neuroimage 2010;49:433-441.
  • Boer ME de, Hertogh C.MPM, Dröes RM, Jonker C, Eefsting JA. Advance directives in dementia: issues on validity and effectiveness. International Psychogeriatrics, 2010 Mar;22(2):201-8.
  • Boer ME, Dröes RM, Jonker C, Eefsting JA, Hertogh CM. Advance directives for euthanasia in dementia: Do law-based opportunities lead to more euthanasia? Health Policy 2010;98:256-262.
  • Bouman AIE, Ettema TP, Wetzels RB, Beek APA. van, de Lange J, Dröes RM. Qualidem: Evaluation of a Dementia-specific Quality of Life Instrument for Persons with Dementia in residential settings; Scalability and Reliability of Subscales used in four Dutch Field Surveys. International Journal of Geriatric Psychiatry 2011 Jul;26(7):711-22.
  • Dröes RM. Mierlo LD van, Roest HG van der, Meiland FJM. Focus and effectiveness of psychosocial interventions for people with dementia in institutional care settings from the perspective of coping with the disease. Non-pharmacological therapies in dementia, 2010;1(2):139-161.
  • Meiland FJM, Reinersmann A, Sävenstedt S, Bergvall-Kåreborn B, Hettinga M, Craig D, Andersson AL, Dröes RM. User-participatory development of assistive technology for people with dementia – from needs to functional requirements. First results of the COGKNOW project. Non-pharmacological therapies in dementia 2010;1(1):71-91.
  • Roest HG van der, Meiland FJ, Jonker C, Dröes RM. User evaluation of the DEM-DISC. Aging and Mental Health, 2010;14(4):461-70.
  • Van Mierlo LD, Van der Roest HG, Meiland FJM, Dröes RM. Personalized Dementia Care; proven effectiveness of psychosocial interventions in subgroups. Ageing Res Rev. 2010 Apr;9(2):163-83.

Boek(hoofdstukken) en vakpublicaties:

  • Boss HM, van den Berg-Vos RM, Scheltens P, Weinstein HC.  Stand van zaken. Vasculaire cognitieve beperking.Ned Tijdschr Geneeskd 2010;154:A1907
  • Gouw, A.A. Proefschriftbespreking: Schade aan kleine hersenvaten op MRI: klinische uitingen en onderligende pathologie.  Tschr Neurol Neurochir 2010;111:180-182.
  • Keulen MA, Uijterwaal MH, Engels MAH, Koene T, Scheltens Ph, Pijnenburg YAL. Taaldiagnostiek bij patiënten met semantische dementie en progressieve niet-vloeiende afasie. Stem-,Spraak- en Taalpathologie 2010;16:239-254.
  • Lemstra E, Eikelenboom P, van Gool P. Cholinerge deficiëtie en cognitie.
  • In: van der Mast R, Heeren T, Kat M, et al. (red.), Handboek ouderen-psychiatrie; 3e dr. Utrecht, de Tijdstroom,2010:511-518.
  • Scheltens Ph. Nog steeds geen pil voor Alzheimer. Ned Tijdschr Geneeskd 2010;154:A1885.
  • Boer ME de, Dröes RM, Jonker C, Eefsting JA, Hertogh CMPM. De beleving van beginnende dementie en het gevreesde lijden. Tijdschrift voor Gerontologie en Geriatrie 2010; 41(5): 194-203.
  • Craig D, Meiland FJM, Passmore AP, Dröes RM. Prevalence and clinical features of dementia. In: Mulvenna MD, Nugent CD. (Eds.), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010, Chapter 2, 15-22.
  • Dröes RM. Omgaan met dementie het psychosociale perspectief. Tijdschrift voor Ouderen-geneeskunde, 2010, 35(5)197-199.
  • Dröes RM. Omgaan met dementie het psychosociale perspectief. Samenvatting oratie.  CaRe-bulletin CaRré, aug 2010.
  • Dröes RM, Bentvelzen SCL, Meiland F, Craig D. Dementia-related and other factors to be taken into account when developing ICT-support for people with dementia – Lessons from field trials, In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 8, 113-130.
  • Gerritsen DL, Dröes RM, Ettema TP, Boelens E, Bos J, Meihuizen L, de Lange J, Schölzel-Dorenbos CJ, Hoogeveen F. Quality of life in dementia, opinions among people with dementia, their professional caregivers, and in literature. Tijdschr Gerontol Geriatr. 2010 Dec;41(6):241-55.
  • Lauriks S, Reinersmann A, Roest H.G. van der, Meiland FJM, Davies RJ, Moelaert F, Mulvenna MD, Nugent CD, Dröes RM. Review of ICT-based services for identified unmet needs in people with dementia, In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 4, 37-62.
  • Martin S, Bengtsson JE, Dröes RM. Assistive technologies and issues relating to privacy, ethics and security. In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 5, 63-78.
  • Meiland F, Dröes RM, Sävenstedt S, Bergvall-Kåreborn B, Andersson AL. Identifying User Needs and the Participative Design Process, In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 6, 79-100.
  • Meiland F, Dröes RM, Sävenstedt S. Measuring the impact of Cognitive Prosthetics on the daily life of people with dementia and their carers In: Mulvenna MD, Nugent CD. (Eds), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 14, 207-220.
  • Mierlo L. & Dröes RM. Dementelcoach; telefonische ondersteuning voor mantelzorgers van mensen met dementie. Vita Valley, Nieuwsbrief, juli 2011.
  • Mulvenna MD, Nugent C, Moelaert F, Craig D, Dröes RM, Bengtsson J. Supporting People with Dementia Using Pervasive Healthcare Technologies, In: Mulvenna MD, Nugent, CD. (Eds.), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag, 2010; Chapter 1, 3-14.
  • Mulvenna MD, Moelaert F, Meiland F, Sävenstedt S, Hettinga M, Craig D, Bengtsson JE, Dröes RM, Martin S. Designing and Evaluating a Cognitive Prosthetic for People with Mild Dementia. In: Brinkman WP, Neerincx M, (Eds), Caring Technology for the Future: Proceedings of the European Conference on Cognitive Ergonomics, 389 pp, Mediamatica, 2010;11-18.
  • Roest HG van der, Meiland FJM, Dröes RM. Proefschrift: Zorgbehoeften bij dementie en digitale, gepersonaliseerde informatievoorziening voor dementiezorg. Verpleegkunde 2010;(3):25-31
  • Sävenstedt S, Meiland F, Dröes RM, Moelaert F. Evaluation of Cognitive Prosthetics In: Mulvenna MD, Nugent CD. (Eds.), Supporting People with Dementia Using Pervasive Health Technologies, Series: Advanced Information and Knowledge Processing, London, Springer-Verlag 2010, Chapter 13, 197-206.

Dissertaties:

  • Altena E. Mapping insomnia: brain structure, function and sleep intervention.
  • Vrije Universiteit Amsterdam 17 maart 2010
  • promotoren: EJW van Someren, DF Swaab, copromotoren: YD van der Werf, Ph Scheltens
  • Tolboom N. Imaging Alzheimer’s disease pathology in vivo: towards an early diagnosis.
  • Vrije Universiteit Amsterdam 12 februari 2010
  • promotoren: Ph Scheltens, AA Lammertsma. copromotoren: BNM van Berckel, WM van der Flier
  • Verwey NA. Biochemical markers in dementia: from mice to men.
  • Vrije Universiteit Amsterdam 16 april 2010
  • promotoren: Ph Scheltens, MA Blankenstein. copromotoren: WM van der Flier, R Veerhuis
Top
Volg ons via